Monarch ProCap ETF MPRO 深 沪
等待开盘 11-06 09:30:00 美东时间
33.59
-0.350
-1.03%
华盛通- 最 高34.04
- 今 开33.95
- 成交量 3.18万股
- 最 低 33.55
- 昨 收 33.9396
- 总市值 2.58亿
- 52周最高 34.04
- 市盈率 静 --
- 换手率 0.41%
- 52周最低 29.819
- 委 比 0.00%
- 总股本 767.42万
- 历史最高 34.04
- 量 比 2.21
- 振 幅 1.44%
- 历史最低 21.5552
- 每 手 1
- 风险率 0.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced that its management will participate in two upcoming investor conferences in November and December 2026: the Jefferies Global Healthcare Conference in London and the 9th Annual Evercore Healthcare Conference in Coral Gables, Florida. The company is developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (PAH), with its Phase 3 clinical trial, IMPROVE-...
10-27 12:00
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
Inhibikase Therapeutics, Inc. announced the appointment of Scott M. Wasserman, MD, to its Board of Directors, effective October 19, 2026, following Dennis Berman's resignation. Wasserman, a cardiologist with over two decades of experience, previously led global development at Amgen and served as Chief Medical Officer at Kailera Therapeutics. He has expertise in clinical trial design, execution, and regulatory interactions. The company anticipates...
10-20 20:01
